TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Affinity DataKi: 20nMAssay Description:Displacement of [3H]-25-hydroxycholesterol from human N-terminal 6His-tagged-RORC2 LBD (259 to 483 residues) expressed in Escherichia coli (DE3) cell...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Affinity DataKi: 20nMAssay Description:Displacement of [3H]-25-hydroxycholesterol from human N-terminal 6His-tagged-RORC2 LBD (259 to 483 residues) expressed in Escherichia coli (DE3) cell...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Affinity DataKi: 50nMAssay Description:Displacement of [3H]-25-hydroxycholesterol from human N-terminal 6His-tagged-RORC2 LBD (259 to 483 residues) expressed in Escherichia coli (DE3) cell...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Affinity DataKi: 1.20E+3nMAssay Description:Displacement of [3H]-25-hydroxycholesterol from human N-terminal 6His-tagged-RORC2 LBD (259 to 483 residues) expressed in Escherichia coli (DE3) cell...More data for this Ligand-Target Pair
Affinity DataKi: 1.80E+3nMAssay Description:Antagonistic activity against M2 muscarinic receptor in guinea pig left atrium derived by plotting log(DR - 1) vs log[antagonist]More data for this Ligand-Target Pair
In DepthDetails
Affinity DataKi: 3.60E+3nMAssay Description:Antagonistic activity against M2 muscarinic receptor in guinea pig left atrium derived by plotting log(DR - 1) vs log[antagonist]More data for this Ligand-Target Pair
In DepthDetails
Affinity DataKi: 4.00E+3nMAssay Description:Antagonistic activity against M2 muscarinic receptor in guinea pig left atrium derived by plotting log(DR - 1) vs log[antagonist]More data for this Ligand-Target Pair
In DepthDetails
Affinity DataKi: 1.10E+4nMAssay Description:Antagonistic activity against M2 muscarinic receptor in guinea pig left atrium derived by plotting log(DR - 1) vs log[antagonist]More data for this Ligand-Target Pair
In DepthDetails
Affinity DataKi: 1.70E+4nMAssay Description:Antagonistic activity against M2 muscarinic receptor in guinea pig left atrium derived by plotting log(DR - 1) vs log[antagonist]More data for this Ligand-Target Pair
In DepthDetails
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Affinity DataKi: 1.90E+4nMAssay Description:Displacement of [3H]-25-hydroxycholesterol from human N-terminal 6His-tagged-RORC2 LBD (259 to 483 residues) expressed in Escherichia coli (DE3) cell...More data for this Ligand-Target Pair
Affinity DataKi: 1.90E+4nMAssay Description:Antagonistic activity against M2 muscarinic receptor in guinea pig left atrium derived by plotting log(DR - 1) vs log[antagonist]More data for this Ligand-Target Pair
In DepthDetails
Affinity DataKi: 3.70E+4nMAssay Description:Antagonistic activity against M2 muscarinic receptor in guinea pig left atrium derived by plotting log(DR - 1) vs log[antagonist]More data for this Ligand-Target Pair
In DepthDetails
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Affinity DataIC50: 3.30nMAssay Description:Inverse agonist activity at RORC2 in human Th17 cells assessed as inhibition of IL17A production after 6 days by sandwich ELISAMore data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Affinity DataIC50: 4.10nMAssay Description:Inverse agonist activity at human N-terminal 6His-tagged-RORC2 LBD (259 to 483 residues) expressed in Escherichia coli (DE3) cells assessed as inhibi...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Affinity DataIC50: 4.80nMAssay Description:Inverse agonist activity at human N-terminal 6His-tagged-RORC2 LBD (259 to 483 residues) expressed in Escherichia coli (DE3) cells assessed as inhibi...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Affinity DataIC50: 5nMAssay Description:Inverse agonist activity at human N-terminal 6His-tagged-RORC2 LBD (259 to 483 residues) expressed in Escherichia coli (DE3) cells assessed as inhibi...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Affinity DataIC50: 5nMAssay Description:Inverse agonist activity at human N-terminal 6His-tagged-RORC2 LBD (259 to 483 residues) expressed in Escherichia coli (DE3) cells assessed as inhibi...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Affinity DataIC50: 5nMAssay Description:Inverse agonist activity at human N-terminal 6His-tagged-RORC2 LBD (259 to 483 residues) expressed in Escherichia coli (DE3) cells assessed as inhibi...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Affinity DataIC50: 5.5nMAssay Description:Inverse agonist activity at human N-terminal 6His-tagged-RORC2 LBD (259 to 483 residues) expressed in Escherichia coli (DE3) cells assessed as inhibi...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Affinity DataIC50: 7.60nMAssay Description:Inverse agonist activity at human N-terminal 6His-tagged-RORC2 LBD (259 to 483 residues) expressed in Escherichia coli (DE3) cells assessed as inhibi...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Affinity DataIC50: 7.90nMAssay Description:Inverse agonist activity at human N-terminal 6His-tagged-RORC2 LBD (259 to 483 residues) expressed in Escherichia coli (DE3) cells assessed as inhibi...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Affinity DataIC50: 9.5nMAssay Description:Inverse agonist activity at RORC2 in human Th17 cells assessed as inhibition of IL17A production after 6 days by sandwich ELISAMore data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Affinity DataIC50: 10nMAssay Description:Inverse agonist activity at human N-terminal 6His-tagged-RORC2 LBD (259 to 483 residues) expressed in Escherichia coli (DE3) cells assessed as inhibi...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Affinity DataIC50: 10nMAssay Description:Inverse agonist activity at human N-terminal 6His-tagged-RORC2 LBD (259 to 483 residues) expressed in Escherichia coli (DE3) cells assessed as inhibi...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Affinity DataIC50: 11nMAssay Description:Inverse agonist activity at human N-terminal 6His-tagged-RORC2 LBD (259 to 483 residues) expressed in Escherichia coli (DE3) cells assessed as inhibi...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Affinity DataIC50: 13nMAssay Description:Inverse agonist activity at human N-terminal 6His-tagged-RORC2 LBD (259 to 483 residues) expressed in Escherichia coli (DE3) cells assessed as inhibi...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Affinity DataIC50: 13nMAssay Description:Inverse agonist activity at RORC2 in human Th17 cells assessed as inhibition of IL17A production after 6 days by sandwich ELISAMore data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Affinity DataIC50: 13nMAssay Description:Inverse agonist activity at human N-terminal 6His-tagged-RORC2 LBD (259 to 483 residues) expressed in Escherichia coli (DE3) cells assessed as inhibi...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Affinity DataIC50: 14nMAssay Description:Inverse agonist activity at RORC2 in human Th17 cells assessed as inhibition of IL17A production after 6 days by sandwich ELISAMore data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Affinity DataIC50: 15nMAssay Description:Inverse agonist activity at human N-terminal 6His-tagged-RORC2 LBD (259 to 483 residues) expressed in Escherichia coli (DE3) cells assessed as inhibi...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Affinity DataIC50: 16nMAssay Description:Inverse agonist activity at human N-terminal 6His-tagged-RORC2 LBD (259 to 483 residues) expressed in Escherichia coli (DE3) cells assessed as inhibi...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Affinity DataIC50: 18nMAssay Description:Inverse agonist activity at human N-terminal 6His-tagged-RORC2 LBD (259 to 483 residues) expressed in Escherichia coli (DE3) cells assessed as inhibi...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Affinity DataIC50: 20nMAssay Description:Inverse agonist activity at human N-terminal 6His-tagged-RORC2 LBD (259 to 483 residues) expressed in Escherichia coli (DE3) cells assessed as inhibi...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Affinity DataIC50: 20nMAssay Description:Inverse agonist activity at human N-terminal 6His-tagged-RORC2 LBD (259 to 483 residues) expressed in Escherichia coli (DE3) cells assessed as inhibi...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Affinity DataIC50: 20nMAssay Description:Inverse agonist activity at human N-terminal 6His-tagged-RORC2 LBD (259 to 483 residues) expressed in Escherichia coli (DE3) cells assessed as inhibi...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Affinity DataIC50: 21nMAssay Description:Inverse agonist activity at RORC2 in human Th17 cells assessed as inhibition of IL17A production after 6 days by sandwich ELISAMore data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Affinity DataIC50: 25nMAssay Description:Inverse agonist activity at RORC2 in human Th17 cells assessed as inhibition of IL17A production after 6 days by sandwich ELISAMore data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Affinity DataIC50: 28nMAssay Description:Inverse agonist activity at human N-terminal 6His-tagged-RORC2 LBD (259 to 483 residues) expressed in Escherichia coli (DE3) cells assessed as inhibi...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Affinity DataIC50: 30nMAssay Description:Inverse agonist activity at RORC2 in human Th17 cells assessed as inhibition of IL17A production after 6 days by sandwich ELISAMore data for this Ligand-Target Pair
Affinity DataIC50: 32nMAssay Description:Inverse agonist activity at RORC2 in BALB/c mouse Th17 cells assessed as inhibition of IL17A production after 4 days by electrochemiluminescence assa...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Affinity DataIC50: 37nMAssay Description:Inverse agonist activity at human N-terminal 6His-tagged-RORC2 LBD (259 to 483 residues) expressed in Escherichia coli (DE3) cells assessed as inhibi...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Affinity DataIC50: 42nMAssay Description:Inverse agonist activity at RORC2 in human Th17 cells assessed as inhibition of IL17A production after 6 days by sandwich ELISAMore data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Affinity DataIC50: 49nMAssay Description:Inverse agonist activity at human N-terminal 6His-tagged-RORC2 LBD (259 to 483 residues) expressed in Escherichia coli (DE3) cells assessed as inhibi...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Affinity DataIC50: 54nMAssay Description:Inverse agonist activity at human N-terminal 6His-tagged-RORC2 LBD (259 to 483 residues) expressed in Escherichia coli (DE3) cells assessed as inhibi...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Affinity DataIC50: 56nMAssay Description:Inverse agonist activity at RORC2 in human Th17 cells assessed as inhibition of IL17A production after 6 days by sandwich ELISAMore data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Affinity DataIC50: 56nMAssay Description:Inverse agonist activity at human N-terminal 6His-tagged-RORC2 LBD (259 to 483 residues) expressed in Escherichia coli (DE3) cells assessed as inhibi...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Affinity DataIC50: 57nMAssay Description:Inverse agonist activity at RORC2 in human Th17 cells assessed as inhibition of IL17A production after 6 days by sandwich ELISAMore data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Affinity DataIC50: 61nMAssay Description:Inverse agonist activity at RORC2 in human Th17 cells assessed as inhibition of IL17A production after 6 days by sandwich ELISAMore data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Affinity DataIC50: 63nMAssay Description:Inverse agonist activity at RORC2 in human Th17 cells assessed as inhibition of IL17A production after 6 days by sandwich ELISAMore data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Karo Bio AB (now Karo Pharma AB)
Curated by ChEMBL
Affinity DataIC50: 64nMAssay Description:Inverse agonist activity at human N-terminal 6His-tagged-RORC2 LBD (259 to 483 residues) expressed in Escherichia coli (DE3) cells assessed as inhibi...More data for this Ligand-Target Pair